Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
This randomized trial was designed to test the effectiveness and safety of rimegepant for the acute treatment of migraine among adults in Japan. Results indicated that rimegepant was more effective than placebo, and the 75 mg dose was observed to be more effective than the 25 mg dose. These results are similar to previous findings from clinical studies in other countries, and suggest that rimegepant can help patients with migraine in Japan.
Authors
- Fumihiko Sakai (ORCID: https://orcid.org/0000-0001-9385-7991)
- Akio Arakawa
- Takao Takeshima (ORCID: https://orcid.org/0000-0003-2678-6956)
- Tomofumi Ishikawa (ORCID: https://orcid.org/0000-0002-0901-368X)
- Koichi Ikeda (ORCID: https://orcid.org/0009-0002-6562-7472)
- Robert Croop (ORCID: https://orcid.org/0009-0004-0151-1192)
- Terence Fullerton
- Alexandra Thiry
- Hiroki Yoshimatsu
- Yasuhiko Matsumori (ORCID: https://orcid.org/0000-0001-5852-0146)
- Yuko Hoshino (ORCID: https://orcid.org/0000-0002-3501-0810)
- Masako Kudo
Institutions
- Iwate Medical University (JP)
- Pfizer (United States) (US)
- Tominaga hospital (JP)
- Biohaven Pharmaceuticals (United States) (US)
- Pfizer (Japan) (JP)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1111/head.14994
- Citations
- 5
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 7.36
Funders
- Pfizer